🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Sarepta tumbles 15% on 9001 decision delay; analysts see a buying opportunity

Published 05/24/2023, 08:55 AM
© Reuters.  Sarepta (SRPT) tumbles 15% as FDA needs more time to complete a review of SRP-9001
SRPT
-

Sarepta Therapeutics (NASDAQ:SRPT) shares fell as much as 14.8% in early Wednesday trading after the medical research company said the U.S. Food and Drug Administration (FDA) informed the company it “requires modest additional time to complete the review” of SRP-9001.

Hence, the PDUFA date for '9001 will be delayed until June 22, 2023, from May 29th.

The therapy is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD).

The company said the FDA also indicated that it intends to potentially grant an accelerated approval for SRP-9001, initially for use in Duchenne patients ages 4-5 years old, once the review is completed.

RBC analysts said the delay "offers concrete timelines."

"Although initial potential label limitation is a slight disappointment, we see limited effect on '9001's medium/long-term opportunity and remain believers into EMBARK and on '9001's long-term prospects. As such, we believe weakness presents a buying opportunity."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.